| Literature DB >> 22554907 |
Rajneesh Srivastava1, Sandipan Ray, Vineet Vaibhav, Kishore Gollapalli, Tulip Jhaveri, Santosh Taur, Snigdha Dhali, Nithya Gogtay, Urmila Thatte, Rapole Srikanth, Sanjeeva Srivastava.
Abstract
Leptospirosis is a zoonotic infectious disease of tropical, subtropical and temperate zones, which is caused by the pathogenic spirochetes of genus Leptospira. Although this zoonosis is generally not considered as fatal, the pathogen can eventually cause severe infection with septic shock, multi-organ failure and lethal pulmonary hemorrhages leading to mortality. In this study, we have performed a proteomic analysis of serum samples from leptospirosis patients (n=6), febrile controls (falciparum malaria) (n=8) and healthy subjects (n=18) to obtain an insight about disease pathogenesis and host immune responses in leptospiral infections. 2DE and 2D-DIGE analysis in combination with MALDI-TOF/TOF MS revealed differential expression of 22 serum proteins in leptospirosis patients compared to the healthy controls. Among the identified differentially expressed proteins, 8 candidates exhibited different trends compared to the febrile controls. Functional analysis suggested the involvement of differentially expressed proteins in vital physiological pathways, including acute phase response, complement and coagulation cascades and hemostasis. This is the first report of analysis of human serum proteome alterations in leptospirosis patients, which revealed several differentially expressed proteins, including α-1-antitrypsin, vitronectin, ceruloplasmin, G-protein signaling regulator, apolipoprotein A-IV, which have not been reported in context of leptospirosis previously. This study will enhance our understanding about leptospirosis pathogenesis and provide a glimpse of host immunological responses. Additionally, a few differentially expressed proteins identified in this study may further be investigated as diagnostic or prognostic serum biomarkers for leptospirosis. This article is part of a Special Issue entitled: Integrated omics.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22554907 PMCID: PMC7185557 DOI: 10.1016/j.jprot.2012.04.007
Source DB: PubMed Journal: J Proteomics ISSN: 1874-3919 Impact factor: 4.044
Fig. 1Differential expression of serum proteins in leptospirosis patients identified in 2DE analysis. (A) Representative 2D gels of serum proteome from healthy controls (n = 18) and leptospirosis patients (n = 6) containing 600 μg depleted serum proteins. Protein samples focused on linear pH 4–7 IPG strips (18 cm) and subsequently separated on 12.5% polyacrylamide gels, were stained with Gel Code Blue Stain. The statistically significant (p < 0.05) down (D) and up-regulated (U) protein spots are marked on 2D gels. (B) The 3D views and bar-diagrammatic representation of few statistically significant down and up-regulated serum proteins identified in patients suffering from leptospiral infection. Data is represented as mean ± SE.
Fig. 2Differential expression of serum proteins in leptospirosis patients identified in 2D-DIGE analysis. (A) Representative 2D-DIGE image of proteins from healthy controls (HC) and leptospirosis patients (L). HC and leptospirosis samples were labeled with Cy3 and Cy5 respectively, while the protein reference pool (internal standard) was labeled with Cy2. (B) Bar-diagram and 3D views of fluorescence intensity of few selected statistically significant (p < 0.05) differentially expressed proteins identified in leptospirosis patients.
List of significant differentially expressed proteins identified in the Leptospirosis patients using 2DE.
| Sl no. | Name of protein with UniProt | Gene name | Fold change | MW | No of spots (spot numbers) | Protein score# | Total ion score# | No. of matched peptides# | Functions⁎ | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ( | APOA1 | 4.39–1.91 | 30.75 | 4 (D-1,D-2, D-4,D-6) | 2.30E − 07 | 815 | 628 | 24 | A,H,I |
| 2 | ( | ALB | 3.4 | 69.32 | 1 (D-3) | 0.00018 | 456 | 386 | 30 | B,D,E,P,Q |
| 3 | ( | APOA4 | 2.96 | 45.34 | 1 (D-5) | 5.80E − 05 | 56 | – | 16 | A,C,D,H,I |
| 4 | ( | C4 | 1.90 | 192.65 | 1 (D-7) | 0.02288 | 492 | 483 | 19 | J,L |
| 5 | ( | SERPINA1 | 2.71–1.47 | 46.71 | 4 (U-1,U-2, U-5,U-6) | 0.0029 | 670 | 538 | 23 | A,F |
| 6 | ( | A1BG | 1.63–1.62 | 54.3 | 2 (U-3,U-4) | 0.0405 | 900 | 821 | 16 | G |
#For proteins with multiple spots in the 2D gels, representative spot detail is provided. Exact values for each spot are provided in supplementary information.
⁎A—protein binding; B—DNA binding; C—metal binding; D—antioxidant activity; E—drug binding; F—peptidase/protease inhibitor activity; G—Plasma Glyco protein, function unknown; H—lipid binding; I—lipid metabolism/transport; J—brain development; K—enzyme regulator activity; L—complement activation; M—blood coagulation; N—antigen/antibody binding; O—catalytic activity; P—cell surface binding; Q—chaperone binding; R—enzyme inhibitor activity.
List of significant differentially expressed proteins identified in the Leptospirosis patients using 2D-DIGE.
| Sl no | Name of protein with UniProt | Gene name | Fold change | MW | No of spots (spot numbers) | Protein score# | Total ion score# | No. of matched peptides# | Functions* | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ( | APOA1 | 2.83–3.01 | 30.75 | 2 (329, 331) | 0.00284 | 815 | 628 | 24 | A,H,I |
| 2 | ( | ALB | 1.76–3 | 69.32 | 3 (117,171, 516) | 0.03566 | 1370 | 1213 | 25 | B,D,E,P,Q |
| 3 | ( | IGHM | 1.73–2.28 | 49.53 | 1 (238, 250) | 0.00521 | 391 | 352 | 11 | N |
| 4 | ( | C3 | 2.21 | 187.05 | 1 (257) | 0.00123 | 207 | 165 | 24 | J,L |
| 5 | ( | CLU | 2.16 | 52.46 | 1 (275) | 0.00168 | 241 | 211 | 10 | A,O |
| 6 | ( | APOA4 | 1.91 | 45.43 | 1 (252) | 0.03608 | 56 | - | 16 | A,C,D,H,I |
| 7 | ( | AHSG | 1.65 | 39.3 | 1(217) | 0.0276 | 405 | 369 | 9 | A,K,R |
| 8 | ( | CFH | 1.27–1.34 | 143.71 | 2(74, 75) | 0.04136 | 778 | 572 | 40 | L |
| 9 | ( | RGS7 | 1.62 | 75.79 | 1(514) | 0.02774 | 28 | – | 12 | A |
| 10 | ( | IGKC | 1.2–1.35 | 11.6 | 3 (312, 322, 332) | 0.03339 | 213 | 191 | 4 | N |
| 11 | ( | SERPINA1 | 1.81–2.29 | 46.7 | 5 (185, 198, 201, 225, 228) | 0.0233 | 667 | 520 | 22 | A,F |
| 12 | ( | VTN | 2.26 | 54.27 | 1 (188) | 0.01282 | 173 | 164 | 5 | A |
| 13 | ( | LRG1 | 1.54–2.05 | 38.15 | 3 (234, 241, 244) | 0.04313 | 634 | 568 | 13 | A |
| 14 | ( | A1BG | 1.30–1.89 | 54.3 | 4 (83,135, 146, 389) | 0.01302 | 900 | 821 | 16 | G |
| 15 | ( | C9 | 1.84 | 63.13 | 1 (85) | 0.03195 | 73 | 73 | 11 | L,M,O |
| 16 | ( | SERPINA3 | 1.40–1.68 | 15.88 | 4 (175, 176, 499, 500) | 0.01572 | 375 | 220 | 27 | A,B,F |
| 17 | ( | CP | 1.19–1.59 | 122.13 | 3 (58, 60, 88) | 0.02839 | 437 | 264 | 35 | C,D,Q |
| 18 | ( | ITIH4 | 1.36 | 103.29 | 1 (86) | 0.01552 | 230 | 153 | 21 | F |
| 19 | ( | CFB | 1.17 | 85.4 | 1 (106) | 0.04961 | 694 | 513 | 30 | A |
| 20 | ( | Apo-E | 1.43 | 36.13 | 1 (84) | 0.00758 | 669 | 573 | 18 | A,H |
| 21 | ( | IGHA1 | 1.15 | 37.63 | 1 (504) | 0.02851 | 612 | 560 | 11 | A,H |
#For proteins with multiple spots in the 2D gels, representative spot detail is provided. Exact values for each spot are provided in supplementary information.
⁎A—protein binding; B—DNA binding; C—metal binding; D—antioxidant activity; E—drug binding; F—peptidase/protease inhibitor activity; G—Plasma Glycoprotein, function unknown; H—lipid binding; I—lipid metabolism/transport; J—brain development; K—enzyme regulator activity; L—complement activation; M—blood coagulation; N—antigen/antibody binding; O—catalytic activity; P—cell surface binding; Q—chaperone binding; R—enzyme inhibitor activity.
Fig. 3Validation of the differential expressions of clusterin and ceruloplasmin by western blot analysis. Western blot analysis of the target proteins: (A) clusterin and (B) ceruloplasmin are represented along with their respective relative intensity using bar-diagrams (relative intensity X 104). Data represents the mean ± SE for healthy controls (HC) (n = 6) and leptospirosis patients (L) (n = 6) analyzed in two independent technical replicates. Densitometry analysis of western blots revealed down-regulation of clusterin and up-regulation of ceruloplasmin in the leptospirosis patients compared to the healthy controls (p < 0.05) that confirmed the results obtained in 2D-DIGE experiment.
Fig. 4Physiological pathways and GO biological process associated with the differentially expressed proteins identified in leptospirosis patients. Pie chart represents (A) pathways (B) biological process obtained in PANTHER analysis. (C) Complement pathways (classical complement pathway, lectin induced complement pathway and alternative complement pathway) identified in DAVID analysis (Biocarta-Pathway Category). Proteins identified in our study are highlighted with black star marks.